With the recognition of these haemodynamic benefits, vasodilators were then studied for their effect on mortality in patients with HF.[ 5 ] The first of these trials, V-HeFT I, was the first major randomised placebo-controlled trial in CV medicine that showed a trend towards mortality reduction with vasodilators.[ 5 ] However, in the late 1980s the paradigm changed from haemodynamics to neurohormonal blockade with the demonstration of mortality benefit with angiotensin-converting receptor inhibitors in HF patients, the superiority of these agents over vasodilat
1
—
—